Head and Neck Cancer Market Exclusive Report with Detailed Study Analysis

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Head and Neck Cancer Market By Products (Abitrexate/ Mexate/ Folex (methotrexate), Hydrea (hydroxyurea), Taxotere (docetaxel), Platinol (cisplatin), 5-fluorouracil (5-FU), Erbitux (cetuximab), Vectibix (panitumumab), Theracim/Theraloc (nimotuzumab), Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tremelimumab and among others) - Clinical Trial/Pipeline Analysis, Market Trends, Industry Competition Analysis, Revenue, and Forecast To 2030."

According to the latest research, the global head and neck cancer market size is valued at US$ 2.44 Billion in 2021, and it is expected to reach US$ 9.07 Billion in 2030, with a CAGR of 16.2% during the forecast period 2022-2030.

Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1217

Head and neck cancer (HNC) is the sixth most prevalent cancer globally, with an estimated 630,000 new cases annually (NCBI study, 2014). Head and neck cancer (HNC) is characterized by squamous cell carcinomas in the nasal cavities, paranasal sinuses, nasopharynx, hypopharynx, oropharynx, oral cavity, skull, and salivary glands. The oral cavity has the highest incidence of malignancy. It is strongly linked to tobacco and alcohol consumption. They are a significant global cause of morbidity and mortality.
Multiple factors drive the head and neck cancer market, including the increasing prevalence of head and neck cancer, the increasing adoption of advanced medical technologies, the reduction of medical errors in cancer care, the various government initiatives for head and neck cancer therapy developments, and the growing public awareness of advanced head and neck cancer (HNC) treatments.
In addition, increasing combination therapies for treating head and neck cancer, as well as rising cigarette smoking, alcohol consumption, and tobacco use, are expected to drive the global head and neck cancer market in the coming years. According to the WHO/Europe Report 2021, tobacco use is the leading cause of lung cancer, accounting for 25 per cent of all cancer fatalities worldwide. It is estimated that approximately 186 million Europeans (or 26% of the adult population) currently use tobacco. Additionally, nearly 11% of all cancer cases in the region were attributed to alcohol in 2018.

However, the high cost of treatments, the adverse effects of available therapies, and the absence of health insurance are significant market restraints.
Geographically, North America dominated the global head and neck cancer market in 2020 due to the increasing prevalence of head and neck cancer, the increasing use of advanced medical technologies, the significant presence of major market players, the high healthcare expenditures, and the awareness of modern cancer treatments.
The Asia-Pacific market is also anticipated to experience the fastest growth over the forecast period (2020-2030) due to the increased demand for head & neck cancer combination therapeutics, the rise in head & neck cancer patients, the ageing population, government initiatives, and high healthcare expenditure.

Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1217

Prominent players operating in the head and neck cancer market are Advaxis, Inc. (U.S.), Amgen, Inc. (U.S.), AstraZeneca plc (U.K.), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (Ono Pharmaceutical Co., Ltd.) (Japan), Cel-Sci Corporation (U.S.), Five Prime Therapeutics, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Incyte Corporation (U.S.), IRX Therapeutics, Inc. (U.S.), MacroGenics, Inc. (U.S.), Merck KGaA (Germany), Novartis AG (Switzerland), Pfizer, Inc., Roche Holdings AG (Genentech) (Switzerland), Viracta Therapeutics (U.S.), and others. The major focus of market players is on strategies like partnerships, collaborations, mergers, agreements, and increasing R&D activities for developing head and neck cancer therapies/treatments. For instance,
• In July 2021, Novartis (Switzerland) collaborated with Kura Oncology, Inc., a clinical-stage biopharmaceutical company, to evaluate the effect of the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma.
• In June 2021, CEL-SCI Corporation (U.S.) announced results from its 9.5-year pivotal Phase 3 study for its immunotherapy Multikine (Leukocyte Interleukin, Injection) in the treatment of advanced (stages III and IV) primary (previously untreated) squamous cell carcinoma of the head and neck (SCCHN). CEL-SCI's Multikine® Immunotherapy produced significant 14.1% 5-year survival benefit (62.7% vs 48.6%) in the group receiving surgery plus radiotherapy in a landmark head and neck cancer phase 3 study.
• In October 2017, Incyte Corporation (U.S.) and MedImmune, AstraZeneca's global biologics research and development arm, expanded their clinical collaboration. As part of the agreement, the companies checked the efficacy and safety of epacadostat, Incyte's investigational selective IDO1 enzyme inhibitor, in combination with AstraZeneca's Imfinzi (durvalumab), a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1217

Market Segments
Global Head and Neck Cancer Market, by Products, 2020-2030 (Value US$ Mn)
• Cytotoxic Agents
o Antimetabolites
 Abitrexate/ Mexate/ Folex (methotrexate)
 Hydrea (hydroxyurea)
o Antitubulins
 Taxotere (docetaxel)
o Others (Platinum Agents, Fluoropyrimidines)
 Platinol (cisplatin)
 5-fluorouracil (5-FU)
• EGFR Inhibitors (mAbs)
o Erbitux (cetuximab)
o Vectibix (panitumumab)
o Theracim/Theraloc (nimotuzumab)
• EGFR Inhibitors (TKIs)
o Tarceva (erlotinib)
 Iressa (gefitinib)
o Tykerb/Tyverb (lapatinib)
• PD1 Inhibitors
o Keytruda (pembrolizumab)
o Opdivo (nivolumab)
• Pipeline Drugs (Late-stage)
o EGFR Inhibitors (mAbs)
 Vectibix (panitumumab)
o PDL1 Inhibitors
 Imfinzi (durvalumab)
 Bavencio (avelumab)
o CTLA4 Inhibitors
 Yervoy (ipilimumab)
 Tremelimumab
Global Head and Neck Cancer Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Head and Neck Cancer Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
 To receive a comprehensive analysis of the prospects for pipeline drugs revenue forecast
 To receive an clinical trial/pipeline analysis and future trends in the head and neck cancer market
 To analyze the head and neck cancer market drivers and challenges
 To get information on head and neck cancer market size (value US$ Mn) and forecast to 2030
 Major investments, mergers & acquisitions in the head and neck cancer market industry

Get more information @
https://www.insightaceanalytic.com/report/global-head-and-neck-cancer-market/1217

Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG